Biopharmaceutical compositions and methods for pediatric patients

The subcutaneous administration of a targeted antibody with specific amino acid sequences effectively treats IL-5-mediated diseases in pediatric patients by reducing eosinophil levels and improving symptoms in pediatric patients with asthma and eosinophilic disorders.

JP2026086897APending Publication Date: 2026-05-26GLAXO SMITHKLINE LLC
0 Cites 0 Cited by

Patent Information

Application Number
JP2026033575
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-01-19
Filing Date
2026-03-03
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

There is a need for effective compositions and methods to treat IL-5-mediated diseases in pediatric patients, particularly asthma and eosinophilic disorders, as existing treatments are inadequate for this population.

Method used

A method involving the subcutaneous administration of a therapeutically effective dose of an antibody with specific heavy and light chain amino acid sequences (SEQ ID NO: 1 and SEQ ID NO: 2) to achieve targeted plasma concentration and area under the curve values, reducing eosinophil levels in pediatric patients with IL-5-mediated diseases.

Benefits of technology

The method effectively reduces eosinophil levels and improves symptoms in pediatric patients with IL-5-mediated diseases, including asthma and eosinophilic disorders, by achieving specific plasma concentration and area under the curve values.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides compositions and related methods for treating interleukin-5 (IL-5) mediated diseases in children. [Solution] A method for treating a disease in a child, comprising the steps of: a) identifying a child weighing less than 40 kg who has a disease selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, etc.; and b) subcutaneously administering a therapeutically effective dose of mepolizumab to the child, wherein the therapeutically effective dose of the antibody results in a maximum plasma concentration (Cmax) of antibody of approximately 10.1960 ± 0.3345 μg / mL and an area under the curve [0-infinity] value of approximately 454.39 ± 15.8876 μg* / mL, thereby treating the disease in the child.
Need to check novelty before this filing date? Find Prior Art